Onco Actu du 22 mars 2017

	2.7 Etiologie - Obésité
Womb cancer risk grows with extra waist weight, study suggests [The Guardian] Researchers writing in the British Medical Journal (BMJ) found that for every increase of 0.1 units in the ratio between waist and hip, the risk of developing the disease increased by 21%.
	3.1 Tabac
Tobacco treaty has helped cut smoking rates, but more work needed [Reuters] In a study published in the Lancet Public Health journal, researchers from Canada's University of Waterloo and the World Health Organization (WHO) found that while progress against what they called the "global tobacco epidemic" has been substantial, it has still fallen short of the pace called for by the treaty.
	4.9 Dép., diag. & prono. - Sein
Genomic screening may help predict breast cancer survival [Stanford Medicine] The study showed that their 12-gene signature was effective at predicting patient survival for two specific subtypes of breast cancer — luminal-A and HER2 — but it wasn’t effective for other subtypes.
	5. Traitements
Patients’ reports may aid prostate cancer treatment choice [STAT] The research bolsters evidence that sexual problems and urinary incontinence are more common after surgery than after radiation or “watchful waiting” without treatment. But it also shows differences in quality of life tend to wane with time for those with prostate cancer that hasn’t spread — the type that affects most men with the disease.
Training viruses to be cancer killers [Cancer Research UK] EnAd has passed these lab examinations and is now being tested in an early stage clinical trial in a very small number of people.
Stem-Cell Based Tool May Help Measure Heart Toxicity of Cancer Drugs [NCI] For the Science Translational Medicine study, Dr. Wu and his colleagues set out to determine if a panel of human stem cell-derived heart cells could be used to evaluate the heart toxicity of 21 different FDA-approved TKIs.
	5.12.1 Immunothérapies - partenariats
Pierre Fabre pens oncology pact with atomic energy spinout [Fierce Biotech] Paris, France-based H-Immune will work with Pierre Fabre to apply its in vitro immunization technology to three immuno-oncology drug discovery programs. In return, Pierre Fabre will cover the cost of R&D and make milestone payments to H-Immune.
Stimunity Signs an Exclusive License Agreement with Institut Curie and Inserm [Stimunity] All started with a fundamental discovery made by the laboratory Innate Immunity at Institut Curie, leads by Dr. Nicolas Manel, Senior Researcher at Inserm and co-founder of Stimunity.
Pierre Fabre and H-Immune Announce Research Partnership to Develop Cancer Immunotherapies [Pierre Fabre] As a newly established bioscience company in the immuno-oncology field and spin out from the French Atomic Energy Commission, H-Immune has developed a proprietary In Vitro Immunization (IVI) technology leveraging a breakthrough approach to generate a series of fully human monoclonal antibodies (mAbs) against any therapeutic target, taking advantage of the affinity maturation processes performed in situ by B lymphocytes.
	5.12.2 Immunothérapies - CAR-T
This is Not a Test: RMAT Designation Goes Live [FDA Voice] Examples include genetically-modified cellular therapies, such as chimeric antigen receptor T-cells (CAR-T cells) and human tissues grown on scaffolds for subsequent use. These products hold great promise in addressing serious unmet medical needs. For example, data from a number of different published studies indicate the potential for CAR-T cells to treat certain relapsed or refractory blood cancers.
	5.12.4 Immunothérapies - Essais
Pembrolizumab Shows Promise in Treatment of Mesothelioma [Penn Medicine] The study, published this month in The Lancet Oncology, is the first to show a positive impact from checkpoint inhibitor immunotherapy drugs on this disease.
	5.12.5 Immunothérapies - Pharma
Struggling Heat gets a warm response to a snapshot on cancer vax data [EndPoints] Its stock surged more than 20% this morning based on an update for a handful of patients taking a combination of HS-110 and Bristol-Myers Squibb’s checkpoint inhibitor Opdivo.
	5.2.3 Pharma - économie
Investors left feeling blue as Cerulean admits defeat on cancer pipeline [Fierce Biotech] Cerulean has been under a cloud since its lead cancer candidate CRLX101 failed a Phase 2 trial last year that tested the drug in combination with Roche's Avastin (bevacizumab) in renal cell carcinoma patients, a form of kidney cancer.
	6.1 Observation
Contraceptive pill protects women against cancer for 35 years, major study suggests [The Telegraph] It means that for every three women who would have developed ovarian or endometrial cancer, one has been protected by taking the pill.
	6.2 Implants mammaires
Breast Implants: Update - Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) [FDA] Patients: Before getting breast implants, make sure to talk to your health care provider about the benefits and risks of textured-surface vs. smooth-surfaced implants. If you already have breast implants, there is no need to change your routine medical care and follow-up.
9 Deaths Are Linked to Rare Cancer From Breast Implants [NY Times] The problem is more likely to occur with textured implants, which have a pebbly surface, than with smooth implants, the agency said. Of the 359 reported cases, 231 included information about the implant surface: 203 were textured, and 28 smooth.
	6.6 Publications
Google Scholar is a serious alternative to Web of Science [LSE Impact Blog] In addition to its flaws having been overstated, Google Scholar’s coverage of high-quality publications is more comprehensive in many areas, including in the social sciences and humanities, books and book chapters, conference proceedings and non-English language publications.
	6.9 Controverses
The bias hunters: Study explores where science goes wrong [Stanford Medicine] “Science,” said Ioannidis, “is the best thing that has happened to humans.” But that doesn’t mean it can’t be improved.